Recent data show that although elevated LDL-C may be well treated, hypertriglyceridaemia is still addressed less effectively. Professor Chris J Packard, Professor of Vascular Biochemistry, Glasgow, UK, reviews evidence on the use of high dose eicosapentaenoic acid (EPA) to lower triglyceride levels and reduce cardiovascular risk, stresses the importance of triglyceride testing, and discusses scenarios for adding high dose EPA or non-statin LDL-C lowering agents to optimised statin therapy.
The challenges of treating FCS and MCS: Where are we now?
As clinical trials of novel therapies show promising TG-lowering effects in patients with familial chylomicronaemia syndrome (FCS) and other forms of severe hypertriglyceridaemia (SHTG), Professor Henry Ginsberg (University of Columbia, New York, USA) discusses the causes, differential diagnosis and management of these challenging conditions.
Triglyceride metabolism and mortality: What is the link?
Higher rates of triglyceride metabolism have recently been linked to increased all-cause, cardiovascular, cancer, and other mortality, but what does it mean for practising clinicians? Professor Børge G. Nordestgaard (University of Copenhagen, Denmark) discusses the new findings and their potential implications.
Are remnants more atherogenic than LDL? Novel genetic insights
Elias Björnson, University of Gothenburg, Sweden, discusses data from a UK Biobank Study which investigated the association between triglyceride-rich lipoproteins/remnant cholesterol and risk of coronary heart disease, and the atherogenicity of those particles compared to low-density lipoprotein particles.
Evinacumab in children with HoFH: What’s the evidence?
Dr Eliot Brinton discusses the unmet need for new treatments for children with homozygous familial hypercholesterolaemia (HoFH), and results of recent studies of evinacumab in children with HoFH aged 5-11 years and in those aged 12-17 years.
The SHASTA-2 trial: What the results mean for clinicians
Professor Daniel Gaudet, University of Montreal, Canada describes the results of the Phase 2b, SHASTA-2 dose-finding trial of plozasiran 10 mg, 25 mg or 50 mg s.c. or matched placebo in patients with severe hypertriglyceridaemia, and discusses what the findings mean for clinicians.
